A Study to Explore Treatment Patterns, Treatment Outcomes, Healthcare Resource Utilization in Adult Participants With Myelofibrosis Through Chart Review
NCT ID: NCT05444972
Last Updated: 2023-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
998 participants
OBSERVATIONAL
2022-08-23
2023-11-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Data from approximately 1000 participants will be collected. No participants will be enrolled in this study.
Participants' charts will be reviewed. No drug will be administered as a part of this study. The duration of the observation period is up to 156 weeks.
There is no additional burden for participants in this trial. All visits must be completed prior to data extraction and participants will be followed for up to 156 weeks.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants Undergoing Chart Review
Participants treated for myelofibrosis undergoing chart review.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have initiated their first treatment on or after the first date when ruxolitinib was approved in their country of residence and no later than 31 December 2021.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB Comprehensive Cancer Center /ID# 252767
Birmingham, Alabama, United States
Wellness Oncology & Hematology /ID# 255591
West Hills, California, United States
Brigham & Women's Hospital /ID# 254312
Boston, Massachusetts, United States
Gabrail Cancer Center Research /ID# 252768
Canton, Ohio, United States
Instituto FIDES /ID# 245526
La Plata, Buenos Aires, Argentina
Hospital Italiano de Buenos Aires /ID# 244373
Ciudad Autonoma Buenos Aires, Ciuadad Autonoma de Buenos Aires, Argentina
Fundaleu /Id# 244371
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma de Buenos Aires, Argentina
Townsville University Hospital /ID# 246585
Douglas, Queensland, Australia
Royal Adelaide Hospital /ID# 246583
Adelaide, South Australia, Australia
Fiona Stanley Hospital /ID# 246584
Murdoch, Western Australia, Australia
Royal Perth Hospital /ID# 246586
Perth, Western Australia, Australia
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein /ID# 247394
São Paulo, São Paulo, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo /ID# 247392
São Paulo, , Brazil
St. Paul's Hospital /ID# 249719
Vancouver, British Columbia, Canada
Nova Scotia Health /ID# 248393
Halifax, Nova Scotia, Canada
Juravinski Cancer Centre /ID# 251334
Hamilton, Ontario, Canada
Princess Margaret Cancer Centre /ID# 249748
Toronto, Ontario, Canada
CSSS Alphonse-Desjardins, CHAU de Levis /ID# 250449
Lévis, Quebec, Canada
CIUSSS de l'est de l'Ile-de-Montreal - Hopital Maisonneuve-Rosemont /ID# 250563
Montreal, Quebec, Canada
Jewish General Hospital /ID# 250674
Montreal, Quebec, Canada
Organizacion Clinica Bonnadona -PREVENIR S.A.S. /ID# 244589
Baranquilla, Atlántico, Colombia
Coorp Hosp Juan Ciudad Sede Hospital Universitario Mayor Mederi /ID# 246108
Bogota DC, Cundinamarca, Colombia
Fundacion Santa Fe de Bogota /ID# 244588
Bogota, Cundinamarca, Colombia
Clínica Imbanaco S.A.S /ID# 248465
Cali, , Colombia
Hospital Pablo Tobon Uribe /ID# 244525
Medellín, , Colombia
General Hospital of Athens Laiko /ID# 246159
Athens, Attica, Greece
University General Hospital Attikon /ID# 246167
Athens, Attica, Greece
University General Hospital of Heraklion PA.G.N.I /ID# 246163
Heraklion, Crete, Greece
General University Hospital of Alexandroupolis /ID# 246161
Alexandroupoli, , Greece
General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 246165
Athens, , Greece
University General Hospital of Ioannina /ID# 246160
Ioannina, , Greece
METAXA Cancer Hospital of Piraeus /ID# 246164
Piraeus, , Greece
University General Hospital of Patras /ID# 246162
RION Patras Achaia, , Greece
Azienda Ospedaliero-Universitaria di Ferrara-Arcispedale Sant Anna /ID# 245149
Cona, Ferrara, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 245335
Rome, Lazio, Italy
Azienda Ospedaliera di Perugia /ID# 245415
Perugia, Umbria, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna /ID# 245716
Bologna, , Italy
ASST Spedali civili di Brescia /ID# 244910
Brescia, , Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 244909
Milan, , Italy
Azienda Ospedaliero Universitaria Maggiore della Carita di Novara /ID# 245566
Novara, , Italy
Azienda Ospedaliera Universitaria Paolo Giaccone /ID# 245075
Palermo, , Italy
ASST Sette Laghi /ID# 245443
Varese, , Italy
Ospedale Belcolle /ID# 245726
Viterbo, , Italy
Hospital de Especialidades CMN SigloXXI /ID# 244748
Mexico City, Mexico City, Mexico
Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 244750
Monterrey, Nuevo León, Mexico
Hospital General de Mexico /ID# 244749
Mexico City, , Mexico
Krzysztof Mądry Praktyka Lekarska /ID# 250485
Warsaw, Masovian Voivodeship, Poland
Specjalistyczna Praktyka Lekarska Witold Prejzner /ID# 250516
Gdansk, Pomeranian Voivodeship, Poland
Joanna Góra-Tybor Specjalistyczna Praktyka Lekarska /ID# 250495
Lodz, , Poland
Specjalistyczna Praktyka Lekarska Grzegorz Helbig /ID# 250515
Orzesze, , Poland
Centro Hospitalar e Universitario de Coimbra, EPE /ID# 244687
Coimbra, , Portugal
Centro Hospitalar Universitario de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 248203
Lisbon, , Portugal
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 244400
Porto, , Portugal
MedLife - Policlinica de Diagnostic Rapid /ID# 244395
Brasov, Brașov County, Romania
Spitalul Clinic Colentina /ID# 245620
Bucharest, , Romania
Institutul Clinic Fundeni /ID# 245939
Bucharest, , Romania
Institutul Oncologic Prof Dr I Chiricuta /ID# 244393
Cluj-Napoca, , Romania
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 250092
Kaohsiung City, , Taiwan
National Taiwan University Hospital /ID# 250093
Taipei, , Taiwan
Gulhane Askeri Tip Academy /ID# 244134
Ankara, , Turkey (Türkiye)
Hacettepe University Medical Faculty /ID# 244131
Ankara, , Turkey (Türkiye)
Dicle Universitesi Tip /ID# 244137
Diyarbakır, , Turkey (Türkiye)
Trakya University Medical Facu /ID# 244132
Edirne, Istanbul, , Turkey (Türkiye)
Bagcilar Medipol Mega Universite Hastanesi /ID# 244133
Istanbul, , Turkey (Türkiye)
Ege University Medical Faculty /ID# 244130
Izmir, , Turkey (Türkiye)
Inonu University Medical Faculty /ID# 244135
Malatya, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gupta V, Tomuleasa C, Barranco Lampon GI, Hou HA, Helbig G, Vachhani P, Symeonidis A, Haznedaroglu I, Galvez K, Tatsch F, Chopra AS, Zhang M, Vizkelety T, Murray B, Ross DM. Real-world treatment patterns and health care resource use for patients with myelofibrosis: results from the METER study. Blood Adv. 2025 Mar 11;9(5):1105-1116. doi: 10.1182/bloodadvances.2024014625.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H23-122
Identifier Type: -
Identifier Source: org_study_id